JP2023503857A5 - - Google Patents

Info

Publication number
JP2023503857A5
JP2023503857A5 JP2022528248A JP2022528248A JP2023503857A5 JP 2023503857 A5 JP2023503857 A5 JP 2023503857A5 JP 2022528248 A JP2022528248 A JP 2022528248A JP 2022528248 A JP2022528248 A JP 2022528248A JP 2023503857 A5 JP2023503857 A5 JP 2023503857A5
Authority
JP
Japan
Prior art keywords
nucleic acid
herv
acid encoding
recombinant mva
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022528248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503857A (ja
JP7644111B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/082926 external-priority patent/WO2021099586A1/en
Publication of JP2023503857A publication Critical patent/JP2023503857A/ja
Publication of JP2023503857A5 publication Critical patent/JP2023503857A5/ja
Application granted granted Critical
Publication of JP7644111B2 publication Critical patent/JP7644111B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022528248A 2019-11-20 2020-11-20 がんを治療するための腫瘍内及び/または静脈内投与用組み換えmvaウイルス Active JP7644111B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19210369.5 2019-11-20
EP19210369 2019-11-20
EP20193706.7 2020-08-31
EP20193706 2020-08-31
PCT/EP2020/082926 WO2021099586A1 (en) 2019-11-20 2020-11-20 Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer

Publications (3)

Publication Number Publication Date
JP2023503857A JP2023503857A (ja) 2023-02-01
JP2023503857A5 true JP2023503857A5 (https=) 2023-11-06
JP7644111B2 JP7644111B2 (ja) 2025-03-11

Family

ID=73740362

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022528248A Active JP7644111B2 (ja) 2019-11-20 2020-11-20 がんを治療するための腫瘍内及び/または静脈内投与用組み換えmvaウイルス

Country Status (11)

Country Link
US (1) US20230190922A1 (https=)
EP (1) EP4061406A1 (https=)
JP (1) JP7644111B2 (https=)
KR (1) KR20220106775A (https=)
CN (1) CN114867491B (https=)
AU (1) AU2020387646A1 (https=)
BR (1) BR112022009798A2 (https=)
CA (1) CA3159588A1 (https=)
IL (1) IL293009B2 (https=)
MX (1) MX2022005664A (https=)
WO (1) WO2021099586A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
WO2023118508A1 (en) * 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
EP4452306A1 (en) * 2021-12-23 2024-10-30 Bavarian Nordic A/S Therapy for modulating immune response with recombinant mva encoding il-12

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
SK4272001A3 (en) 1998-10-05 2003-02-04 Pharmexa As Methods for therapeutic vaccination
UA76731C2 (uk) 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
DE60235041D1 (de) 2001-11-30 2010-02-25 Us Gov Health & Human Serv Und ihre verwendung
EP2345665A3 (en) 2001-12-04 2012-02-15 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
NZ592082A (en) 2008-11-27 2013-03-28 Bavarian Nordic As Promoters for recombinant viral expression
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
EP2800762B1 (en) 2012-01-03 2018-01-03 The United States of America, as represented by the Secretary, Department of Health and Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
WO2013189611A1 (en) 2012-06-22 2013-12-27 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
EP2908851A1 (en) 2012-10-19 2015-08-26 Bavarian Nordic Inc. Methods and compositions for the treatment of cancer
EP2912183B1 (en) 2012-10-28 2020-05-06 Bavarian Nordic A/S Pr13.5 promoter for robust t-cell and antibody responses
KR102499737B1 (ko) * 2014-05-13 2023-02-13 버베리안 노딕 에이/에스 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법
KR20150135148A (ko) 2014-05-23 2015-12-02 주식회사 제넥신 Pd-l1 융합 단백질 및 이의 용도
ES2901468T3 (es) 2015-07-31 2022-03-22 Bavarian Nordic As Promotores para mejorar la expresión en poxvirus
CN111050790B (zh) 2017-08-24 2024-07-12 巴法里安诺迪克有限公司 通过静脉内施用重组mva和抗体治疗癌症的组合疗法
DK3676285T3 (da) * 2017-09-01 2026-01-19 Inprother Aps Vaccine til anvendelse i profylakse og/eller behandling af en sygdom
CA3119503A1 (en) * 2018-11-20 2020-05-28 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l

Similar Documents

Publication Publication Date Title
JP2023503857A5 (https=)
JP2022507744A5 (https=)
Schlom Therapeutic cancer vaccines: current status and moving forward
JP2017515841A5 (https=)
JP2018139586A5 (https=)
Wiedermann et al. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
CA2293692A1 (en) Methods and reagents for vaccination which generate a cd8 t cell immune response
RU2016148311A (ru) Комбинированная терапия для лечения рака с помощью рекомбинантного поксвируса, экспрессирующего опухолевый антиген, и антагониста или агониста молекулы иммунной контрольной точки
WO2004016643A3 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
Lubaroff Prostate cancer vaccines in clinical trials
JP2023503858A5 (https=)
Chang et al. Vaccinating against cancer: getting to prime time
US12246038B2 (en) Compositions for inducing an immune response
JP2022512595A5 (https=)
Wang et al. Current status and progress of the development of prostate cancer vaccines
Shu et al. Virus-like particles presenting the FGF-2 protein or identified antigenic peptides promoted antitumor immune responses in mice
Evans et al. Vaccine therapy for cancer—fact or fiction?
Ruan et al. Enhanced synergistic anti‐Lewis lung carcinoma effect of a DNA vaccine harboring a MUC 1‐VEGFR 2 fusion gene used with GM‐CSF as an adjuvant
Lin et al. Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer
Kudo-Saito et al. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity
RU2015116904A (ru) Иммунизация вектором на основе вируса бешенства, экспрессирующим чужеродный белковый антиген
RU2021117499A (ru) Терапия для лечения рака с помощью внутриопухолевого и/или внутривенного введения рекомбинантного mva, кодирующего 4-1bbl (cd137l) и/или cd40l
Azimifar et al. Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies
WO2007058235A1 (ja) 融合蛋白質およびその薬学的用途
Shahreza et al. GRP-based vaccines as a novel approach in cancer immunotherapy: mechanisms, challenges, and prospects